20.500.12556/DiRROS-24719 Addressing cardiovascular toxicities of Bruton tyrosine kinase inhibitors in chronic lymphocytic leukaemia practical recommendations for haematologists in central and eastern Europe Advances in understanding the biology of chronic lymphocytic leukaemia (CLL) translated into revolutionary treatments with improved survival outcomes. Consequently, the traditional chemoimmunotherapy courses shifted to targeted therapies, including inhibitors of the Bruton tyrosine kinase (BTKis). BTKis correlate with an increased risk over time of toxicities of the cardiovascular (CV) system, which require proper management. An expert meeting involving 14 haematology and cardiology opinion leaders from 5 Central Eastern European countries was held, aiming to find pragmatic approaches for haematologists to identify the CLL patients at CV risk before starting the BTKis therapy, and further recognize, manage and monitor de novo cardiotoxicities occurring under treatment. Geographical variations have been described, including availability of reimbursed BTKis, national registries, and presence of cardio-oncology units. The experts discussed controversies, unmet needs and potential solutions by exemplifying local challenges and best practices. Each patient requires a personalized strategy based on multiple factors, hence practical pathways to follow during the continuity of care in CLL patients requiring BTKis have been proposed. Rigorous evaluation of the CV risk, periodic assessments of cardiotoxicity during BTKis treatment and work in multidisciplinary teams are vital for managing CV complications without unnecessary interruptions of the CLL treatment. CLL chronic lymphocytic leukemia BTK inhibitors cardiovascular toxicity cardio-oncology BTK zaviralci kronična limfocitna levkemija KLL kardioonkologija true false true Angleški jezik Slovenski jezik Neznano 2025-12-15 13:36:14 2025-12-15 13:36:15 2025-12-16 03:44:30 0000-00-00 00:00:00 2025 0 0 Nasl. z nasl. zaslona; Opis vira z dne 17. 11. 2025; str. 1-12 issue 1, [article no.] 102 Vol. 11 2025 0000-00-00 Zaloznikova Objavljeno NiDoloceno 0000-00-00 0000-00-00 0000-00-00 616.1 2057-3804 10.1186/s40959-025-00394-7 257382403 RAZ_Aurer_Igor_2025.pdf RAZ_Aurer_Igor_2025.pdf 1 A00D1BF723BFD5C646D8198F0179E8D4 16e5bc8c3ef2bed7760a6137af9096ae34a7ae1ea25e911c0db79c9c55117432 d3d3fb21-d9b2-11f0-94a7-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=36926 https://link.springer.com/article/10.1186/s40959-025-00394-7 0 e14bb464-d9b2-11f0-94a7-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=36928 Univerzitetni klinični center Ljubljana 0 0 0